The Globe and Mail reports in its Tuesday edition that Brookfield Asset Management has teamed up with the family behind Spanish drug maker Grifols SA, which has been expanding into Canada, to put together a possible bid to take the pharmaceutical company private. The Globe's James Bradshaw and Chris Hannay write that Grifols said on Monday that members of its founding family, who own nearly 30 per cent of the company's shares, and Brookfield have asked for company information to evaluate a potential joint bid that would delist the company from Spanish stock exchanges and Nasdaq. The Grifols board held an "extraordinary meeting" to consider the request on Sunday. Brookfield confirmed in its own statement "that it has held exploratory discussions" with shareholders about a making an offer. Spain's Cinco Dias newspaper reported that the suitors could make a final offer in the coming weeks, and that the deal could be worth 5.5 billion euros ($8.1-billion). Grifols is a Spanish multinational pharmaceutical company that specializes in producing blood plasma-based products, which are part of life-saving medicines used to treat people with compromised immune systems from cancer treatment, autoimmune disorders or other reasons.